Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."
Under a license agreement, Biopredic will leverage Preci’s expertise and production capacity in sourcing primary hepatocytes, and combine with its own IP and know-how in cell pooling. The partnership will provide DMPK researchers access to large batches of high-performing suspended pooled hepatocytes with extended longevity from multiple donors.
Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."
Moshe Zilversmit, Co-Founder and CEO of Signum Surgical, commented: “The completion of our clinical trial marks a significant milestone for Signum Surgical and our BioHealxTM device. We look forward to submitting our De Novo classification request to the U.S. FDA and the scientific publication of the data in due course, as we seek to bring this novel treatment to market for the benefit of patients, surgeons, and the healthcare system.”
Associate Professor Eunah Kang and Mr. Youngjun Kim from the School of Chemical Engineering and Material Science at Chung-Ang University, Korea have recently come up with an elegant solution. The duo has developed an electrochemical DNA biosensor using a graphitic nano-onion/molybdenum disulfide (MoS2) nanosheet composite, which effectively detects human papillomavirus (HPV)-16 and HPV-18, and can serve as an early diagnosis of cervical cancer.
"We are delighted to enter into this collaboration with Gustave Roussy, a leading comprehensive cancer center in Europe and worldwide,” said Corinne Danan, general manager of Veracyte’s Biopharma business unit. “This partnership will enable us to augment our Veracyte Biopharma Atlas reference database with a large number of patients tumor samples and data from innovative cancer therapies. Ultimately, we believe this tool may help our biopharmaceutical partners accelerate development of new, precision-medicine therapies that improve outcomes for patients with cancer.”
“Following our recent achievement of market authorization for our RemeOs™ screw in the U.S., we are continuing to explore materials and technologies to expand our portfolio of trauma products. This grant will contribute to our efforts. We are deeply appreciative of Business Finland's trust and support, recognizing Bioretec's capabilities and the consortium's dedication to delivering intelligent medical devices to a demanding global market." said Timo Lehtonen, CEO of Bioretec.
Carisma notes the presentation includes data from group 1 (n=9) and group 2 (n=5). Patients in both groups received the same total dose (up to 5x109 CT-0508) either via a fractionated, multi-day infusion regimen (group 1) or via a single-day bolus infusion (group 2).
Umami Bioworks and Maruha Nichiro will be working to build the infrastructure of Japan’s cultivated seafood industry together in this partnership. The strategic investment from Maruha Nichiro will help accelerate Umami’s development progress.
In 2023, CAR T cell therapy can cost between $500,000 and $1,000,000. Being one of the most expensive Medicare diagnosis-related drugs, the collection and manufacturing of T cells plays a large role in this excessive cost. Akadeum Life Sciences microbubble technology provides a more economical, cost-effective solution that is faster, and more adept at maintaining cell physiology.
Azri Azerai, Executive Chairman of Malaysian Genomics, expressed optimism about MGRC's future, stating: "MGRC achieved higher revenue in the current quarter as compared to the preceding quarter's revenue of RM0.68 million, mainly generated from cell and gene therapy products. Our state-of-the-art BSL-2 cell processing lab, cGMP approved by MOH for production of cell and gene therapies, illustrates our technological advancement. Hence, we foresee that we will obtain higher revenue from cell and gene products in the next quarter."
By using this website you agree to accept Medical Device News Magazine Privacy Policy
